Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anna Teschemaker"'
Publikováno v:
HemaSphere, Vol 7, p e03128c0 (2023)
Externí odkaz:
https://doaj.org/article/a7d6f40ce0f544fb9007d8fb1c32b5e2
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:HSR23-119
Publikováno v:
Journal of Medical Economics. 26:454-462
Cholangiocarcinoma (CCA) is associated with poor prognosis. Healthcare-related management likely presents a substantial economic burden associated with time away from work in patients with CCA. To assess productivity loss, associated indirect costs,
Publikováno v:
Blood. 140:7025-7027
Autor:
Shreekant Parasuraman, Anna Teschemaker, Jonathan K. Kish, Kristin M. Savill, Philomena Colucci
Publikováno v:
Blood. 140:6854-6855
Autor:
Smitha Sivaraman, Susan Snodgrass, Anna Teschemaker, Shreekant Parasuraman, Scott Bunner, Dilan Paranagama, Lincy S. Lal
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:HSR20-104
Autor:
Milind Javle, Sunyoung Lee, Nilofer S Azad, Mitesh J Borad, Robin Kate Kelley, Smitha Sivaraman, Anna Teschemaker, Ishveen Chopra, Nora Janjan, Shreekant Parasuraman, Tanios S Bekaii-Saab
Publikováno v:
The oncologist. 27(10)
Background Previous studies report increasing cholangiocarcinoma (CCA) incidence up to 2015. This contemporary retrospective analysis of CCA incidence and mortality in the US from 2001-2017 assessed whether CCA incidence continued to increase beyond
Publikováno v:
Journal of Clinical Oncology. 40:392-392
392 Background: CCA pts, often diagnosed at older age with advanced disease, face poor prognoses and economic burden. Despite increasing CCA incidence in working age pts, little is known on financial impact on working pts. This study describes the im
Autor:
Suthakar, Sabapathy, Cheryl, Neslusan, Kim, Yoong, Anna, Teschemaker, Pierre, Johansen, Michael, Willis
Publikováno v:
Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique. 23(2)
BackgroundCanagliflozin, an agent that inhibits sodium glucose co-transporter 2, is approved as add-on to metformin plus sulfonylurea for the treatment of type 2 diabetes in Canada. Canagliflozin offers greater glycemic control, as well as important